ProCE Banner Activity


Education and Resources to Optimize Patient Care in Hepatocellular Carcinoma

Text Module

Get up to date on systemic therapies for advanced hepatocellular carcinoma in this interactive text module reviewing the latest clinical data on first-line and second-line treatment regimens.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 01, 2023

Expiration: January 31, 2024

No longer available for credit.



Stacey Stein

Stacey Stein, MD

Associate Professor of Medicine
Department of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported by an educational grant from


Target Audience

This educational program is intended for oncologists and other healthcare professionals who treat and manage patients with hepatocellular carcinomas.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with hepatocellular carcinoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan evidence-based and guideline-driven individualized care for patients with advanced HCC, both in the frontline and second-line treatment setting
  • Evaluate the rationale and available data for immune checkpoint inhibitor–based combinations across the continuum of HCC care
  • Select patients with HCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Stacey Stein, MD: consultant/advisor/speaker: AstraZeneca, Eisai, Exelixis, Genentech, Imvax, Ipsen, Merck, QED.

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Nathan Beach, PhD, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Jim Mortimer has no relevant financial relationships to disclose.

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 01, 2023, through January 31, 2024:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.